Holen Sie sich die Stockscreener-App
19.35
1.12%
-0.22
Vorhandelsmarkt:
19.35
Schlusskurs vom Vortag:
$19.57
Offen:
$19.82
24-Stunden-Volumen:
556.59K
Relative Volume:
0.53
Marktkapitalisierung:
$1.55B
Einnahmen:
$123.67M
Nettoeinkommen (Verlust:
$-38.63M
KGV:
-31.36
EPS:
-0.617
Netto-Cashflow:
$-27.50M
1W Leistung:
+1.79%
1M Leistung:
+13.22%
6M Leistung:
+57.19%
1J Leistung:
+317.93%
1-Tages-Spanne:
$18.82
$19.97
1-Wochen-Bereich:
$18.50
$19.97
52-Wochen-Spanne:
$3.51
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
19.35 | 1.55B | 123.67M | -38.63M | -27.50M | -0.617 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Planned Monte Rosa (GLUE) CEO share sale under Rule 10b5-1 - Stock Titan
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496 - Investing.com
Form 144 | Monte Rosa Therapeutics(GLUE.US) Officer Proposes to Sell 103.45 Million in Common Stocks - Moomoo
Monte Rosa Therapeutics (GLUE) Form 144: RSU 21,865; Markus Warmuth sales listed - Stock Titan
GLUE SEC FilingsMonte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Expands By 18.2% - MarketBeat
[ARS] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan
Executive pay and audits headline Monte Rosa (NASDAQ: GLUE) 2026 proxy - Stock Titan
GLUE Price Today: Monte Rosa Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Monte Rosa Therapeutics, Inc. (GLUE) Presents at AACR Annual Meeting 2026Slideshow - Seeking Alpha
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates - MSN
GLUE (Monte Rosa Therapeutics Inc.) stock rises after Q4 2025 earnings even as quarterly losses exceed analyst expectations.Trending Social Stocks - UBND thành phố Hải Phòng
What is the sentiment on Monte Rosa (GLUE) stock today | Q4 2025: Earnings UnderperformCrowd Trend Signals - Cổng thông tin điện tử tỉnh Lào Cai
Dimension funds and principals disclose stakes in Monte Rosa Therapeutics (NASDAQ: GLUE) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Palvella Therapeutics (PVLA) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Gains Biotech Spotlight - Kalkine Media
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors - Sahm
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise - The Globe and Mail
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today - simplywall.st
Monte Rosa presents preclinical data on cancer drug candidate By Investing.com - Investing.com India
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2026 on the Potential of its Cyclin E1 -directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors - Investing News Network
Is Monte Rosa (GLUE) stock worth trading today (Eye on Rally) 2026-04-20Viral Trade Signals - Cổng thông tin điện tử Tỉnh Sơn La
Monte Rosa presents preclinical data on cancer drug candidate - Investing.com
Monte Rosa Therapeutics unveils preclinical data on targeting undruggable CCNE1 in solid tumors - Traders Union
Monte Rosa Therapeutics Presents Preclinical Data at - GlobeNewswire
Form 144 MONTE ROSA THERAPEUTICS For: 16 April By Investing.com - Investing.com India
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Eastern Progress
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 22.2% - MarketBeat
GLUE (NASDAQ: GLUE) insider notifies sale of 18,683 shares via option - Stock Titan
Monte Rosa Therapeutics CEO to join AACR2026 panel on proximity-induced therapies - Traders Union
GLUE Stock: CEO Markus Warmuth Sells 8,000 Shares April 14 - Meyka
Insider Sell Alert: Markus Warmuth Sells 8,000 Shares of Monte R - GuruFocus
Warmuth, Monte Rosa Therapeutics CEO, sells $141k in Glue stock - Investing.com Australia
Warmuth, Monte Rosa Therapeutics CEO, sells $141k in Glue stock By Investing.com - Investing.com South Africa
[Form 4] Monte Rosa Therapeutics, Inc. Insider Trading Activity - Stock Titan
Markus Warmuth sells 5,466 shares of GLUE (NASDAQ: GLUE) under Rule 144 - Stock Titan
Edmund Dunn files Form 144 reporting GLUE (NASDAQ: GLUE) common stock sales - Stock Titan
Insider Sell: Philip Nickson Sells Shares of Monte Rosa Therapeu - GuruFocus
Monte Rosa Therapeutics Insider Sells Over $100K in Shares - National Today
Philip Nickson Sells 5,845 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock - MarketBeat
Insider at Monte Rosa Therapeutics (GLUE) sells 5,845 shares - Stock Titan
[144] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan
26,117 GLUE shares reported for sale (NASDAQ: GLUE) in Form 144 - Stock Titan
GLUE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):